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Accepted 20 July 2012AbstractThe relationship between hormones and endometrial cancer is well known because disease states, such as chronic anovulation and
endogenous estrogen production from hormone-secreting tumors (for example, granulosa cell tumor of the ovary), are related to excess estrogen,
and unopposed estrogen use might lead to endometrial overgrowth, hyperplasia, and subsequent development of endometrial carcinoma.
Therefore, the possibility of using antihormone therapy in endometrial carcinoma and/or its precancer lesions, such as simple hyperplasia with
and without atypia and complex hyperplasia with and without atypia, is always supposed, as in the management of breast cancer. In addition, if
women in whom endometrial cancer is diagnosed are very young, some critical issues should be considered, including the possibility of ovary
preservation-partial preservation of fertility and the possibility of both ovary and uterus preservation-complete preservation of fertility. Other
factors are also important to consider and include oncologic risk, appropriateness of candidates for treatment, type of hormone use, response rate
of hormonal therapy, appropriate surveillance, and additional counseling for issues such as anxiety about relapse and metastasis, distress about
side effects, advice of the family, advice of the medical staff, and economic burden.
This review will be focused on updated information and recent knowledge of the use of hormones in the management of younger women with
endometrial cancer who want fertility preservation.
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Uterine corpus cancer, with an estimated 606,910 cases
(8% of gynecologic cancers) in the United States, second only
to breast cancer (n ¼ 2,971,610; 41%), is common among
women who have survived endometrial cancer [1]; therefore, it
is a concern in gynecologic oncology. Although the incidence
of uterine corpus cancer is still lower in developing countries
than in developed countries, there has been a significantly
increasing trend toward a greater number of endometrial
cancer cases in recent years in Taiwan and other Asian
countries [2], suggesting that many more gynecologic oncol-
ogists in Taiwan might be interested in this topic. Uterine
corpus cancer can be classified into two major distinguishing
tumors: endometrial cancer or uterine sarcoma. On the basis of
biologic and histopathologic variables, endometrial cancer can
be further broken down into two major typesdone is strongly
associated with unopposed estrogen (Type I), but the other
may be relatively unrelated to the overproduction of estrogen
(Type II) [3e6]. In the 2007 issue of the Taiwanese Journal of
Obstetrics and Gynecology, Liu [7] reviewed the characteris-
tics of endometrial cancer extensively and focused on the
molecular carcinogenesis of endometrial cancer. In this article,
additional updated information is provided and hormone
therapy in endometrial cancer is discussed.
Type I and Type II endometrial cancer
Types I and II endometrial cancers have distinct biologic
and histopathologic differences (Table 1).
Type I endometrial cancers account for more than 80% of
cases with favorable outcomes, and are frequently associated
with unopposed estrogen or hyperestrogenic environments;
they are usually an endometrioid type [7]. A series of carci-
nogenic changes in Type I endometrial cancers are often found
in the pathologic review. The severity can be initiated from
endometrial hyperplasia without atypia and upgraded to
a more severe status; for example, complex endometrialTable 1
The characteristics of Type I and Type II endometrial cancers.
Type I
Incidence 80%
Age Premenopause, perimenopause, and postmeno
Histologic subtype Endometrioid
Grade Low
Clinical behavior Indolent
Estrogen-related Strong
Obesity Often
Parity Frequently nulliparous
Presence of precursor lesion Often and frequent
EIN or hyperplasia with/without atypia
Immunohistochemical staining PTEN gene: approximately 50e80%
MSI: approximately 20e45%
K-ras mutation: approximately 10e30%
b-catenin: 20%
Frequent positive to hormone receptors, such
AR ¼ androgen receptor; EIC ¼ endometrial intraepithelial carcinoma; EIN ¼ endo
mixed mullerian tumor; MSI ¼ microsatellite instability; PR ¼ progesterone recehyperplasia with atypia (atypical complex hyperplasia, ACH)
or well-differentiated (Grade 1) endometrial cancer. In addi-
tion, the histologic type of Type I endometrial cancer is often
endometrioid, and is of a low grade (Grade 1 or 2), with
frequently positive immunohistochemical staining for the
phosphatase and tensin homolog (PTEN) gene (approximately
50e80%), or microsatellite instability (approximately
20e45%), K-ras mutation (approximately 10e30%) or
b-catenin (20%), and hormone receptors, such as estrogen
receptors, progesterone receptors, or androgen receptors (ARs)
[7,8]. The sources of unopposed estrogen exposure can be
exogenous, including hormone replacement therapy (HRT) in
postmenopausal women [9e11], or endogenous, such as
obesity or anovulation status [12]. Obesity contributes to an
increased rate of endometrial cancer, although endogenous
estrogen is always considered the most important factor.
However, there is no doubt that some endocrines, paracrines,
cytokines, and growth factors related to obesity might further
influence this result. For example, insulin resistance, hyper-
glycemia, and hyperinsulinemia can significantly increase
insulin growth factor bioavailability, which promotes endo-
metrial proliferation by insulin growth factor-1 receptor
signaling [6,13]. Type I endometrial cancer is the most
common extracolonic malignancy if endometrial carcinomas
occur in familial penetration (approximately 2e5% of all
endometrial cancer in Western countries) in multiorgan cancer
syndrome, such as hereditary nonpolyposis colorectal carci-
noma (HNPCC)/Lynch syndrome; the lifetime risk of endo-
metrial cancer varies between 32% and 60% in Lynch
syndrome compared with 1% in the general population [14].
Type II endometrial cancer is often related to age. For
example, it frequently occurs in older postmenopausal women,
without dependence on estrogen stimulation, and often arises in
an atrophic environment. The histology includes papillary
serous, clear cell, and poorly differentiated carcinomas with
a tendency to invade the lymphatic and vascular spaces, metas-
tasize to lymph nodes, and microscopically involve other intra-
peritoneal structures despite minimal or no invasion within theType II
20%
pause Postmenopause
Serous, clear, (MMMT?)
High
Aggressive
Weak
Rare
Rarely nulliparous
Arguable
EIC
p53 mutations: 90%
E-cadherin: approximately 80e90%
HER-2/neu overexpression: approximately 45e80%
p16 mutation
as ER, PR, or AR
metrial intraepithelial neoplasia; ER ¼ estrogen receptor, MMMT¼malignant
ptor; PTEN ¼ phosphatase and tensin homolog.
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rates, and a poor prognosis. Immunohistochemical staining is
often positive for p53 mutations (90%), E-cadherin alteration
(approximately 80e90%), and HER-2/neu overexpression
(approximately 45e80%), and of most importance, is frequently
negative for hormone receptors, such as ERs or PRs [7].Staging and standard treatment for younger women with
endometrial cancer
Endometrial cancers commonly present in an early stage
and are staged surgically according to the 2009 French
Federation Internationale de Gynecologie et d’Obstetrique
(FIGO) staging system, a revision of the 1988 FIGO staging
system [15,16]. The major differences between the 1988 and
2009 FIGO staging systems for endometrial cancers include
the following: (1) the 1988 FIGO IA and IB are combined into
the 2009 FIGO IA, and the 1988 FIGO IC is now the 2009
FIGO IB; (2) Stage II no longer has a subset A and B, and
endocervical glandular invasion is considered as Stage I; (3)
positive cytology no longer is part of Stage III; and (4) pelvic
and para-aortic lymph node invasion is classified as Stage IIIC,
based on the poor prognosis [15].
Because endometrial cancer has a surgicopathologic
staging system (FIGO) and most cases are estrogen-related,
the standard treatment for endometrial cancer includes
cytology, total hysterectomy (TH), and bilateral salpingo-
oophorectomy (BSO) with/without the requirement of lymph
node sampling and lymph node dissection, although some
argue that the 2009 FIGO recommendations still fail to
adequately address the controversies in surgical staging [17].
Hysterectomy results in the loss of fertility and is often an
unacceptable treatment for women of childbearing age
[18e21].
In younger women with endometrial cancer who want to
preserve fertility, two strategies can be used: partial preser-
vation of fertility or complete preservation of fertility.
Partial preservation of fertility can be achieved by TH alone
without BSO in selected patients with disease confined to the
uterus, based on the concept that ovarian preservation in young
women with early-stage endometrial cancers [22] and HRT in
women with early-stage endometrial cancer after TH and BSO
[23,24] might be safe. Partial preservation of fertility is clearly
demonstrated in the data from the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) study,
which showed that ovarian preservation had no effect on either
cancer-specific or overall survival in these younger and/or
premenopausal women with early-stage endometrial cancer
[22]. Complete preservation of fertility is mediated through
dilation and curettage with or without hysteroscopy to remove
endometrial lesions only and followed by various types of
hormone therapy, especially progestins, to offer the opportu-
nity to preserve both the uterus and ovaries, based on prom-
ising data from a recent review showing that 77.7% of patients
demonstrated a response to hormonal therapy and 53.2% had
a durable complete response [25]. However, beforeconsidering the possibility of fertility preservation, some
important issues should be considered.
The incidence and 5-year survival rate of endometrial
cancer diagnosed in women younger than 40 years
According to the most recent cancer statistics in the
United States [1], an estimated 47,130 new cases of endo-
metrial cancer will be diagnosed in 2012; more than 90% of
these cancers develop in the endometrium and 68% are
diagnosed at an early stage. The 5-year survival rate is 95.8%
for localized disease in the United States [1] and 99.0%,
98.6%, and 98.7% for 1988 FIGO IA, 1988 FIGO IB, and
2009 FIGO IA, respectively, at Taipei Veterans General
Hospital [16]. Because it is reported that 5% of patients with
endometrial cancer are younger than 40 years, and of most
importance, the prognosis of this population is excellent
(most of these cases are relatively well-differentiated Type I
endometrioid cancers or diagnosed as ACH), a strategy of
partial or total fertility preservation in these younger women
might be possible. In addition, these prognosis-favorable
endometrial cancers often occur in nonfertile women [26],
suggesting that many younger women in whom endometrial
cancers are diagnosed have not completed childbearing, and
the need to preserve fertility is high.
Partial preservation of fertility
As mentioned previously, the standard treatment for endo-
metrial cancers is TH and BSO. BSO is typically performed in
conjunction with TH to exclude occult ovarian metastases and
to decrease estrogen production, which might be beneficial in
endometrioid cancer treatment because this type of cancer is
an estrogen-responsive tumor. Despite the theoretical benefits
of oophorectomy during endometrial cancer treatment, this
procedure results in complete loss of fertility and surgical
menopause with the subsequently increasing risk of long-term
sequelae of estrogen deprivation, such as cardiovascular
disease or osteoporosis [27e29].
Although ovarian preservation offers the potential for future
oocyte retrieval as a family-building option and would also
avoid the immediate consequences of estrogen deprivation, as
mentioned previously, this strategy may lead to the potentially
fatal risk of overlooking occult ovarian metastases and coex-
isting synchronous ovarian primary tumors and the potential
risk of endocrine stimulation of residual microscopic endo-
metrial cancers [30,31]. A large study conducted by the
Gynecologic Oncology Group (GOG), enrolling 621 patients
with Stage I endometrial cancers, showed that an appreciable
number of patients (22%, 144 of 621) with Stage I endometrial
cancers and undergoing complete surgical staging have
disease outside of the uterus (lymph node metastasis, adnexal
disease, intraperitoneal spread, and/or malignant cells in
peritoneal washing) [32]. In addition, although most reports
showed that clinical Stage I endometrial cancer with metas-
tasis to the ovary is rare, the incidence of any stage of endo-
metrial cancer with a synchronous ovarian malignancy is as
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incidence in women older than 45 years with endometrial
cancer [33]. It is fortunate that premenopausal women with
concomitant ovarian and endometrial cancers often had Stage I
ovarian cancers, and that women with Grade I tumors of each
type of cancer had an excellent prognosis after surgical
management [33]. However, many recent studies have failed
to support this concept.
For example, a retrospective study of 976 women in China
with clinical Stage I endometrial cancer showed that the
incidence of coexisting ovarian cancer in clinical Stage
I endometrial cancer was low (2.05%; 1.74% with ovarian
metastases and 0.31% with synchronous ovarian primary
cancer) [34]. Among these patients, 50% (10 of 20) had
microscopic ovarian involvement, with an incidence of 1.3%.
However, these data should be used with caution because
many risk factors could be identified that contributed to these
unusual findings, including 40% of patients (8 of 20) identified
as Grade 3, 15% (3 of 20) as nonendometrioid type, and 45%
(11 of 20) as cervical invasion. The authors found that cervical
invasion (2009 FIGO Stage II), uterine serosa extension (2009
FIGO Stage IIIA), and fallopian tube involvement (2009 FIGO
Stage IIIA) were independent high-risk factors for ovarian
metastases in clinical Stage I endometrial cancer [34], sug-
gesting that patients with 2009 FIGO Stage I are still a low-
risk population for ovarian metastases.
A Korean report of 260 patients with early-stage endome-
trial cancer, including 204 2009 FIGO Stage I patients (78.5%)
showed that 7.31% of patients (19 of 260) had coexisting
ovarian malignancy (12 metastatic and 7 synchronous primary
malignancies), and identified the independent risk factors,
such as intraoperative extrauterine disease, nonendometrioid
histology, lymph node metastasis, and patient age, for those
with coexisting ovarian cancers [35]. In addition, of the 206
patients without any evidence of intraoperative extrauterine
disease, the coexisting ovarian cancer rate was 0.97% (2 of
206), and none were younger than 45 years [35]. The Korean
Gynecologic Oncology Group (KGOG) performed a nation-
wide study to determine whether ovarian preservation is
feasible in younger patients with endometrial cancer with
a median follow-up of 55 months [36]. Although seven of the
175 patients (4.0%) had documented recurrence, no recur-
rences were observed in Stage I patients with endometrioid
histology, suggesting that ovarian preservation does not
adversely affect the recurrence of early-stage endometrial
cancer [36]. In a Yale University (USA) study enrolling 251
patients with endometrial cancer who were younger than 45
years, including 189 patients (75.3%) with FIGO Stage
I disease, 58.2% of patients (146 of 251) underwent an
adequately surgically staged procedure and no difference in
survival was found between clinically or surgically staged
patients in the group of Stage I patients who underwent TH
and BSO and those who underwent TH only, and there was no
statistically significant difference in overall survival in the
group of Stage I patients with or without BSO [37]. In addi-
tion, ovarian preservation had no significant influence on
disease-free survival in patients with Grade 1 disease [37].The data of the SEER study, including 402 patients (12%)
who had ovarian preservation out of a total of 3269 women 45
years of age or younger with Stage I endometrial cancers,
showed that 5-year survival was similar between the patients
who received TH with and without the ovarian preservation,
and 5-year survival was 98% for patients with 1988 FIGO IA
endometrial cancers, regardless of whether the ovaries were
preserved or moved [22]. Among patients with 1988 FIGO IC
(2009 FIGO IB) endometrial cancer, survival was 89% [95%
confidence interval (CI) ¼ approximately 83e96%] in women
who underwent BSO, compared with 86% (95%
CI ¼ approximately 63e100%) in those who had ovarian
preservation. Multivariate Cox proportional hazards models of
survival based on performance of BSO showed that ovarian
preservation had no effect on either cancer-specific [hazard
ratio (HR) ¼ 0.58; 95% CI ¼ 0.14e2.44] or overall
(HR ¼ 0.68; 95% CI ¼ approximately 0.34e1.35) survival,
suggesting that ovarian preservation in these younger and/or
premenopausal women with early-stage endometrial cancer
may be safe and not increase cancer-related mortality [22].
The concern regarding ovarian preservation is that
continued ovarian estrogen production might increase the risk
of endometrial cancer recurrence. Although the previously
mentioned studies [22,34e37] showed that overall survival
rate was similar between the patients with TH with and without
BSOs, other prospective trials, which were designed for the
evaluation of the risk of HRT in endometrial cancer survivors
[38,39], might strengthen the concept of the safety of ovarian
preservation in endometrial cancer survivors. The GOG study
was designed to determine the effect of estrogen replacement
therapy on the recurrence rate and survival of 1236 women
who had undergone surgery for Stage I or II endometrial cancer
[38]. With a median follow-up of 35.7 months, the absolute
recurrence rate in the estrogen-treated arm was 2.3% compared
with 1.9% in the placebo arm, which contributed to 0.8%
mortality in the estrogen-treated patients (5 of 618) and 0.6%
mortality in the placebo arm (4 of 618). These results sup-
ported the safety of exogenous estrogen with regard to the risk
of endometrial recurrence, although this study was not
complete [38]. A prospective randomized study aimed to
evaluate the effect of immediate estrogen plus progestin
therapy on the oncologic outcome of patients with endometrial
cancers. Fifty patients received therapy and showed that
immediate postoperative use of HRT did not increase recur-
rence or death in a median follow-up of 49.1 months [39].
Ovarian preservation might be safe in situations in which
patients with endometrial cancer are younger than 45 years;
have 2009 FIGO Stage I endometrial cancer; Grade 1 or Grade
2 cancer; endometrioid type cancer; and no grossly extra-
uterine tumors. Other situations could be individualized based
on a careful calculation of the risk-benefit ratio when the
patients decide in favor of ovarian preservation.
Total preservation of fertility
Although ovarian preservation can provide women with the
opportunity of future fertility, it is still a major ethical and
Table 2
Fertility-sparing treatment of endometrial cancers or endometrial precursor
lesions: questions and possible answers.
Questions Possible answers
Oncologic risk 1. Persistent or progressive: approximately
14.4e25.4%
2. Complete response with recurrence:
approximately 23.2e35.4%
Good candidate 1. Younger than 40 y
2. Has a desire to preserve fertility
3. Has a need to give birth
4. Has the ability to give birth
5. Can become pregnant immediately
after tumor regression
6. Endometrioid endometrial carcinoma
7. Severity less than or equal to
Grade 1 on experts’ review
8. Diseases limited to 2009 FIGO IA
by imaging (diagnostic tools, including MRI,
laparoscopy, if required); the best
is 1988 FIGO IA
9. Good compliance
10. No contraindication for high-dose
progestin or other hormone therapies
Response rate 1. Initial response: approximately 74.6e85.6%
2. Complete response:
approximately 48.2e65.8%
Hormone type MPA
Megestrol
Progestin intrauterine device
LNG-IUD plus GnRH agonist
Hormone dosage Approximately 200e800 mg MPA
Approximately 80e320 mg megestrol
Surveillance Every 2e6 months
Reproductive outcome Approximately 34.8e41%
Counseling A team effort
FIGO ¼ International Federation of Gynecology and Obstetrics; GnRH
agonist¼ gonadotropin-releasing hormone agonist; LNG-IUD¼ levonorgestrel-
release intrauterine device; MPA ¼ medroxyprogesterone; MRI ¼ magnetic
resonance imaging.
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accepted in some countries or societies. In addition to pres-
ervation of the ovary, an additional preservation of the uterus
seems to be more reasonable for most patients who want to
preserve their fertility. However, this attempt is really more
challenging than preserving the ovary alone and sacrificing the
uterus. It is a major challenge not only for the patients but also
for the doctors. The main concern is the risk of persistent
tumors, tumor recurrence, and tumor-associated morbidity or
mortality. The patients with endometrial cancer who want
uterus preservation can present with two distinguishing clin-
ical conditions. One is that the tumor confined to the uterine
cavity has been removed completely and the other is that
rescue therapy can eradicate the residual tumors completely. In
addition, the use of effective rescue treatment without further
compromising fertility is a key step toward success in the
conservative management of women with endometrial cancer.
To achieve this goal, several concerns should be addressed. A
recent review from Kesterson and Fanning [40] tried to
respond to these six major concerns: oncologic risk, appro-
priate candidates, response rate of hormonal therapy, type of
hormone use, appropriate surveillance, and additional coun-
seling. The concerns and possible explanations (Table 2) are
presented in detail in the next paragraphs.
Kitamura [41] has tried to clarify the criteria that cancer
patients use to set priorities in their treatment choices using the
analytic hierarchy process, a mathematical decision-making
method that includes the alternatives “to receive treatment”
and “to not receive treatment,” and five criteria: anxiety about
relapse and metastasis, distress about side effects, advice of
the family, advice of the medical staff, and economic burden.
The author found that anxiety about relapse and metastasis and
advice of the medical staff were the most important factors in
making a treatment choice [41]. This finding can be used to
respond to the concerns of women with early-stage endome-
trial cancer and a desire to preserve their fertility.
Oncologic risk
The oncologic risk may be the most important concern, but
there are many controversial issues. As shown previously, one
is the possible presence of extrauterine diseases related to
Stage I endometrial cancers, and that conservative treatment
might miss these lethal conditions. For example, an earlier
study from the GOG Study Group in 1987 showed that 22% of
patients with Stage I endometrial cancer might have diseases
outside of the uterus [32]. The same study showed grade and
depth of invasion as independent risk factors related to
extrauterine disease [32].
In addition, the risk of coexistence of synchronous ovarian
cancer, especially an endometrioid type, might be high,
particularly in younger women with endometrial cancer
[35,42e44]. In general, the phenomenon of synchronously
arising malignancies of the female genital tract appears to be
more common in the younger group than in the older group
[44]. One report evaluating 1365 patients with endometrial
cancers, with 44 women younger than 45 years and 1321 olderthan 45 years, found synchronous ovarian malignancies
occurred in six patients (14%, 6 of 44) in the young group
compared with 23 (2%, 23 of 1321) in the older group [44].
The authors still concluded that a conservative approach is
a meaningful quality of life goal for patients with cancer, but
suitable only for a limited number of patients. For example,
eight patients (18%, 8 of 44) in the young group had FIFO
Stage IA, Grade 1 disease and may have been eligible for
fertility-sparing treatment, corresponding to an incidence rate
of 0.3/100,000 [44].
All above-mentioned oncologic risks, such as probably
coexistence of diseases outside of the uterus, or coexistence of
synchronous ovarian cancer in these early-stage endometrial
cancers, questioned the acceptability of conservative treatment
for endometrial cancer. Therefore, oncologic risk can be
minimized if patients with endometrial cancer have disease
limited to a low grade (the best is Grade 1) and minimal
muscular invasion or no myometrial invasion [the best is 1988
FIGO IA and endometrial intraepithelial neoplasia (EIN), but
not endometrial intraepithelial carcinoma].
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What types of patients with endometrial cancer are
appropriate candidates for fertility preservation? To respond to
this question, the following factors should be considered: the
desire to preserve fertility in the presence of endometrial
cancer; the need to bear children (and of most importance, the
ability to give birth); and the desire to become pregnant
immediately after tumor regression. Therefore, younger age
might be one of the most critical factors because fertility
declines with increasing age [12,45,46].
Other important factors include confirmation of the severity
of disease by experts, diseases limited to a low grade and
minimal myometrial invasion (as discussed previously),
absence of extrauterine spread, good compliance, and absence
of a contraindication to medical treatment.
Confirmation of disease severity includes grade diagnosis
and myometrial invasion of the disease by experts; however,
the consistency (pathological diagnosis-agreement between
the different experts or different evaluation time) is still
questionable. For example, pathologic experts are required for
grade and differential diagnosis. ACH harbors a broad spec-
trum of differential diagnoses [47]. All forms of hyperplasia
may share specific morphologic features, including an increase
in the gland-stroma ratio, irregularities in gland shape, and
variation in gland size and shape [47]. Morphologic features of
atypical hyperplasia can be evaluated in three parts, including
nuclei (stratification with loss of polarity, enlarged and
rounded with irregular shapes, coarsening of chromatin
creating a vesicular appearance, prominent nucleoli, mitotic
activity), varied amount of cytoplasm (eosinophilia, diffuse or
focal), and appearance of glands (often markedly increased
gland-stroma ratio) [48]. However, sometimes hyperplasia is
difficult to distinguish from benign abnormalities or more
severe forms of endometrial cancer. Cytologic changes in
atypia might be confused with cytoplasmic changes in meta-
plasia [48].
ACH can be considered an immediate precursor of EIN.
EIN, a monoclonal endometrial preinvasive glandular prolif-
eration, is the immediate pathologic precursor of endometrioid
endometrial adenocarcinoma, with a long-term cancer risk 45-
fold greater than that of its benign endometrial hyperplasia
counterparts, although this classification cannot replace the
recent World Health Organization (WHO) classification [49].
Diagnostic features of EIN must fulfill the following: for
architectural evaluation, including that the area of the glands
exceeds that of the stroma (glands/stroma > 1) and the lesion
is composed of individual glands and may branch slightly and
vary in shape; for cytology, including that nuclear and/or
cytoplasmic features of the epithelial cells differ between
glands with abnormal architecture and those with a normal
background, and may include change in nuclear polarity,
nuclear pleomorphism, or altered cytoplasmic differentiation,
and the presence of a highly abnormal cytology if no normal
comparison glands are present; for size, that they should not
exceed 1 mm in maximum linear dimension, after excluding
the mimic lesion, including benign or cancer statuses, such asbenign conditions with overlapping criteria: disordered
proliferative, basalis, secretory, polyps, repair, etc.; and
carcinoma, if maze-like glands, solid areas, or significant
cribriforming is present [49].
Sometimes ACH might be missed or associated with well-
differentiated adenocarcinoma because patients undergoing
a hysterectomy soon after the biopsy/curettage diagnosis of
ACH have a final diagnosis of endometrioid carcinoma, with
an incidence ranging from 17% to 43% of cases [50e52], even
though well-differentiated adenocarcinoma can be diagnosed
when one of three essential criteria is met, including
a confluent gland pattern, an extensive papillary pattern, and
a desmoplastic stroma response [48]. A multicenter European
study was designed to assess intraobserver and interobserver
agreement in the diagnosis of endometrial lesions by five
expert European gynecologic pathologists, and found a lack of
agreement in the diagnoses of ACH and lack of reproducibility
in the recognition of the histologic features of stromal alter-
ations to differentiate ACH from well-differentiated adeno-
carcinoma in endometrial biopsy or curettage specimens [50].
Radiologic experts and good imaging studies such as
magnetic resonance imaging (MRI) are needed to evaluate
myometrial invasion or extrauterine involvement. A recent
KGOG study showed that using the CA-125 blood test and
MRI as criteria provided accurate differentiation of a low-risk
group from a lymph node metastasis group among patients
with endometrial cancer, because the false- negative rate was
1.4% in the validation cohort (43% of 360 patients) with good
discrimination (area under the receiver operator curve ¼ 0.85)
[53]. In addition, the native likelihood ratio of the low-risk
criteria was 0.11 (95% CI ¼ 0.04e0.29), and the false-
negative rate was 1.3% (95% CI ¼ 0.5e3.3%) at the
assumed prevalence of nodal metastasis of 10% [53].
The use of 3.0 T MRI to evaluate the depth of myometrial
invasion by endometrial cancer, and whether there is myo-
metrial invasion, has high diagnostic accuracy, with 95%
sensitivity, approximately 60e70% specificity, 91e93% posi-
tive predictive value, 75e78% negative predictive value, and
a total accuracy of 88e90% [54]. In distinguishing cases of no
and superficial myometrial invasion from cases of deep myo-
metrial invasion, 3.0 T MRI had 88e94% sensitivity, 94e97%
specificity, 83e93% positive predictive value, 94e97% nega-
tive predictive value, and 92e94% accuracy [54].
Good compliance without a contraindication for high-dose
hormonal therapy, mainly progestins, is also an important
selection criterion for good candidates. Good compliance is
a basic requirement not only for the treatment of many chronic
diseases or surgical illnesses [55e58] but also for women with
endometrial cancer who wish to preserve their fertility,
because compliance with follow-up and the taking of long-
term medication is important. A repeat follow-up examina-
tion including a surgical approach (for example, dilation and
curettage or laparoscopy examination) might sometimes pose
problems for some patients, but it is needed because of the
oncologic risk inherent in these patients. Therefore, if the
patients are not able to have good compliance, the possibility
of fertility preservation should not be suggested. Finally,
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with a contraindication for hormonal therapy. The treatment
for endometrial cancer is often a hormone-like agent, which
may involve the hepatic metabolism and affect hemostasis or
mood change. However, there are no specialized reports
addressing the absolute contraindications for frequently used
agents for hormonal therapy in endometrial cancer. Therefore,
the labeling guidance text for progestin-only oral contracep-
tives can be used a reference. A Category 3 or 4 contraindi-
cation for progestin treatment includes a history of or current
breast cancer, liver disease (i.e., severe cirrhosis) or liver
tumors (hepatocellular adenoma or hepatoma), and use of
medications to treat seizures or tuberculosis (i.e., phenytoin,
carbamazepine, barbiturates, primidone, topiramate, oxcarba-
zepine, or rifampicin) [59]. Less common side effects of high-
dose progestins include headaches, tender breasts, nausea,
dizziness, weight gain, acne, thrombosis, and extra hair on the
face and body [60]. In a recent self-screening survey for the
use of progestin-only oral contraceptive pills, only 1.6% of
women were identified as having at least one contraindication
for progestin-only oral contraceptive pills, with a sensitivity
rate of 75% (95% CI ¼ approximately 50.6e90.4%), and
0.6% of women in a prospective study of oral contraceptive
use reported having a contraindication for progestin-only oral
contraceptives [59], which emphasizes again that the advice
of medical staff is one of the most important factors in
treatment choice.
Type of hormone use
How to select an appropriate conservative treatment agent
for women with endometrial cancer is also an important issue.
A Web-based survey of all United Kingdom consultant gyne-
cologists (n ¼ 338) from the Royal College of Obstetricians
and Gynecologists showed that the most popular choices for
managing complex endometrial hyperplasia were oral
progestins (33.2%, 109 of 338) and the levonorgestrel intra-
uterine system (LNG-IUS) (52.1%, 171 of 338); most gyne-
cologists (52.6%) would explore two conservative choices
before attempting to perform a hysterectomy for this condition
[61]. By contrast, for ACH, more than 80% of gynecologists
(83.2%, 273 of 338) would perform a hysterectomy and would
only consider LNG-IUS or oral progestins as a second or third
option [61]. It is interesting that more gynecologists (57.6%,
155 of 269) favored the use of LNG-IUS as a secondary choice
in the management of women with ACH [61].
The published data on the conservative treatment of women
with endometrial ACH or endometrial cancer seem to differ
from those of the above survey. A recent systematic review
summarized 45 studies with 391 women (median age of 31.7
years, ranging from approximately 19 years to 80 years),
including 111 patients in whom a diagnosis of ACH was made
and 280 patients in whom a diagnosis of endometrial cancer
was made [25]. The study data and recommendations are
presented later in this paragraph, and only the types of
hormones are discussed in this section. Progestin agents
included medroxyprogesterone acetate (MPA), megestrolacetate, LNG-IUS, intramuscular 17-hydroxyprogesterone,
oral contraceptives, norethisterone, dihydrogesterone, natural
progesterone, and combinations of two agents [25]. Of the
progestins used to treat these patients, most (49%) were
MPAs; 25%, megestrol acetates; 19%, LNG-IUS; 5.3%,
natural progesterones; 0.8%, intramuscular progesterone
treatment; and the remaining were nonspecified treatments
[25]. The dosage use for these patients with ACH or endo-
metrial cancer varied greatly: MPA ranged from 200 mg to
800 mg, and megestrol acetate ranged from 40 mg to 320 mg.
Some gynecologists have favored the use of LNG-IUS in
the management of patients with ACH or endometrial cancer
[62]. Of 12 patients who had a 36-month follow-up with LNG-
IUS treatment, the endometrial biopsy results were negative in
seven of 11 (63.6%) at 6 months and in six of eight (75%) at
12 months, suggesting that LNG-IUS can eradicate some cases
of presumed Stage IA, Grade 1 endometrioid cancer in women
at high risk for perioperative morbidity [62]. In addition,
a small prospective observational study showed that 16 of 19
patients with ACH had regression within 12 months of LNG-
IUS treatment, and only two patients were treated with TH due
to persistent disease [63]. However, a systematic review
investigating the efficacy of LNG-IUS for endometrial
protection was less confident in its support for recommending
LNG-IUS as the treatment of choice for hyperplasia. In
addition, there was no evidence to adequately support the use
of LNG-IUS as chemoprevention in women with a risk factor
for future endometrial cancer, such as HNPCC syndrome or
obesity, although its use might be of benefit in reducing the
risk of endometrial polyps and hyperplasia in tamoxifen users
[64], who are often survivors of breast cancer, and be signif-
icantly risky for patients with endometrial cancer [65e69].
Experience with the sole use of LNG-IUS in the setting of
endometrial cancer is still limited, and evidence is needed.
Therefore, oral progestin or other hormone therapy, for
example, gonadotropin-releasing hormone agonist (GnRH
agonist) [70e73], antiprogestins [73], selective progesterone
receptor modulators (SPRMs) [74,75], estrogen receptor
antagonists, such as fulvestrant [76], aromatase inhibitors [75],
or new-generation progestin [77], should be added in patients
treated with LNG-IUS [25,78].
Response rate with hormonal therapy
The overall response rate with hormone therapy in patients
with ACH and endometrial cancer, when the uterus is
preserved, has been described earlier (staging and standard
treatment for younger women with endometrial cancer
section) (Table 2). In the meta-analysis of 45 studies cited in
the previous section, including 391 patients (the median age of
31.7 years, ranging from 19 years to 80 years), Gunderson et al
[25] summarized the reports from 111 women in whom
a diagnosis of ACH was made and 280 women in whom
a diagnosis of endometrial cancer was made [25]. The median
follow-up time was 39 months, ranging from 2 months to 138
months, with a complete response in 304 women (77.7%) [25].
Median time to complete response in 226 patients was
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and eight women (53.2%) had a complete response with no
evidence of recurrence; 96 women (24.6%) had an initial
response, but finally had recurrence with a median time to
recurrence of 24 months, ranging from 4 months to 72 months;
87 women (22.2%) failed to respond to hormonal therapy [25].
The safety of fertility preservation in women seems to be
much more acceptable for those with ACH, because these
patients not only need little time to achieve complete remis-
sion but also have a higher percentage of complete remissions.
Durable response and initial response rates for ACH (65.8%
and 85.6%) were significantly higher than for endometrial
carcinoma (48.2% and 74.6%), respectively [25].
Appropriate surveillance
Appropriate and close surveillance is of the most impor-
tance for these patients because oncologic risks are always
present and any delay in adequate treatment may result in
a fatal outcome for these patients. In addition, the potential
risk of hormone treatment should be emphasized. For
example, thrombosis is a serious adverse reaction to high-dose
progestin, caused by the high-dose progestin’s inhibitory
activity against plasminogen activators, which might result in
cerebral infarction, myocardial infarction, and pulmonary
embolism; therefore, monthly checks of the clotting system
are suggested, and treatment with high-dose progestin needs to
be discontinued upon detection of any abnormality in the
clotting system [77]. Furthermore, cancer tissue susceptibility
to hormone treatment is important in avoiding the potential
risk of cancer persistence and progression. It has been shown
that the susceptibility of ACH and endometrial cancer to
hormone therapy varies among individual cases, with
responses more likely to appear in cases of ACH and less
likely in cases of endometrial cancer, especially in higher
grade tumors, such as Grade 2 or more. Therefore, the
surveillance of patients undergoing fertility preservation might
differ between those with ACH and endometrial cancer.
A meta-analysis review that reported the need for a minimum
of 3 months of progestin therapy for ACH patients before
assessing response and longer for patients with endometrial
cancer, the danger of concomitant adnexal malignancy, and theTable 3
Domestic experience in the management of young women with endometrial atypi
Authors (y) Patients Hormone CR rate
Kung [88] (1997) 22 y/o M, T,
Oral pills
100%
Wang [89] (2002) (n ¼ 9) 32 y/o (30e39) M, T, GnRH-a 88.9% (
Huang [89] (2005) 36 y/o 100%
Chang [91] (2006) (n ¼ 2) 35 y/o
35 y/o
MPA
Oral pills
Wu [92] (2008) 35 y/o M 100%
Chao [93] (2011) (n ¼ 3) 30 y/o
31 y/o
32 y/o
M þ T
M
100%
CR ¼ complete remission; FU ¼ follow-up; GnRH-a ¼ gonadotropin releasing hor
old; MPA ¼ medroxyprogesterone; T ¼ tamoxifen; TH ¼ total hysterectomy.considerable risk of disease recurrence all mandate close
follow-up and definitive surgical therapy if needed [25].
Although most patients with endometrial cancer who can be
managed with conservative treatment are predicted to have
a response to hormone therapy, a thinning of the endometrium
on transvaginal ultrasound is associated with an increased
chance of responding to progestin therapy [78]. However, the
predictive value cannot be considered as an alternative to
endometrial sampling or repeat dilation and curettage. There is
no agreement yet on a checkup list for patients with endo-
metrial cancer with uterus preservation. Therefore, the
following suggestions may need further validation. First,
regular transvaginal ultrasound and/or Pap smear every 3
months are recommended, and the thickness of the endome-
trium should be less than 5 mm. Second, repeat endometrial
sampling and/or Pap smear should be performed every 3e6
months because the Pap smear sometimes can detect abnormal
cells from the extracervix [79,80]. Third, MRI or laparoscopy
can be performed annually or semiannually if indicated
[81,82]. Fourth, childbearing should be planned as soon as
possible, and if there is no immediate attempt to become
pregnant, continuing hormonal therapy is highly recom-
mended. Fifth, more definite therapy should be sought in case
of any suspicion of nonresponders during follow-up.
Additional counseling
Although almost all endometrial cancer is sporadic, there is
no doubt that genetics plays a role in the pathogenesis. For
example, Lynch syndrome or HNPCCda disorder of hereditary
mutation in DNA mismatched repair genesd presents a rela-
tively high lifetime risk for endometrial cancer (27e71%
compared with 3% in the general population). Not only is there
a high risk of endometrial cancer in patients with Lynch
syndrome, but also a high risk of colon, ovarian, genitourinary,
and gastrointestinal carcinomas. Another syndrome with PTEN
mutations is Cowden syndrome, an autosomal-dominant
inherited disorder that results in breast, endometrial, thyroid,
kidney, and colorectal cancers, as well as dermatologic condi-
tions, including hamartomas. Patients with these hereditary
disorders, similar to a BRCA1 mutation, should be referred for
genetic counseling. Identification of patients with this geneticcal complex hyperplasia or cancer who underwent uterus preservation.
Recurrent rate Birth TH FU
NA NA NA 12 mo
8/9) 50% (4/8) 22.2% (2/9) 66.7% (6/9) 69 mo
(25e113 mo)
100% 100% 100% 4 mo
100% NA NA 24 mo
0% 100
(3/3)
100% 11 y
(8e16 y)
mone agonist; M ¼ megestrol acetate; mo ¼ months; n ¼ number; y/o ¼ years
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additional cancer prevention strategies. Finally, because anxiety
about relapse and metastasis and advice of the medical staff are
the most important factors for treatment choice in cancer
patients [41], a team [83], including special gynecologic
oncologists [84], psychosocial experts [85], cytogenetic experts
[86], and reproductive endocrinologists [87], etc., should be
included in consultations for these early endometrial cancer
patients who need fertility preservation.
The Taiwan experience
Six reports can be found with domestic data [88e93]
(Table 3). As early as 1997, Kung et al [88] reported
a 22-year-old nulliparous woman with concomitant early-stage
endometrial cancer and polycystic ovary syndrome who was
treated with multimodality and sequential treatment, including
repeat endometrial curettage, a 6-month megestrol acetate and
tamoxifen treatment, a combination of contraceptive pills,
hysteroscopy, and laparoscopy,with a successful preservation of
the uterus [88]. The largest series, from Chang Gung Memorial
Hospital, supported the feasibility of an active and multimodal
treatment strategy in nulliparous young patients with well-
selected Stage I, Grade 1 endometrial cancers [89], although
almost all patients finally needed TH for definite therapy,
even those patients without clinically evident disease [93].
Conclusion
Fertility preservation therapy for young women with ACH
or endometrial cancer is still not a standard therapy, although
it is a reasonable choice. Before attempting this approach
certain concerns should be adequately explored between the
patient and physician, including the choice of either complete
or partial preservation of fertility. Other concerns include the
high oncologic risk, even in patients with a high response rate.
Careful counseling for anxiety about relapse and metastasis,
distress about side effects, advice of the family, advice of the
medical staff (teamwork), and the economic burden should be
included in the decision-making process.
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